Brief: Pherecydes Pharma Receives Go-Ahead From Ethics Committee For PhagoDAIR Study
07/02/2022 16:56
Feb 7 (Reuters) - Pherecydes Pharma SA ALPHE.PA :
* RECEIVES A FAVORABLE OPINION FROM THE ETHICS COMMITTEE TO
INITIATE THE PHAGODAIR STUDY
* FIRST RESULTS OF STUDY ARE EXPECTED IN SUMMER OF 2023
* THIS ETHICS COMMITTEE APPROVAL WILL ALLOW PATIENT
ENROLLMENT TO
BEGIN DURING SPRING OF 2022 AS ANTICIPATED
* PHAGODAIR IS A PHASE I/II CLINICAL STUDY FOR TREATMENT OF
OSTEOARTICULAR INFECTIONS OF PROSTHESES DUE TO STAPHYLOCOCCUS
AUREUS
Source text for Eikon: ID:nBw4550Sra
Further company coverage: ALPHE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Pherecydes Pharma SA
See all newsBrief: Erytech And Pherecydes Announce Merger And Name Change To Phaxiam Therapeutics
Brief: Pherecydes Pharma SA - Pherecydes Pharma And Erytech Pharma Shareholders Approve Merger Between Two Companies To Create Phaxiam Therapeutics
Brief: Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
Brief: Erytech: urges shareholders to vote for merger with Pherecydes and dismisses Akkadian's moves
Brief: Erytech Pharma Says Akkadian Has Initiated Proceedings To Postpone Vote On Merger With Pherecydes